Federal Circuit Reinforces Standard for Prior Art Enablement in CRISPR Dispute
Alert
Arkansas Bans PBMs from Owning Pharmacies, Escalating Scrutiny of Vertical Integration in Pharmacy Distribution
Alert
Federal Circuit Clarifies Standard for Patent Conception in Ongoing CRISPR Dispute
Alert
AI’s Expanded Role in the Life Sciences Regulatory Review Process: Key Developments in U.S. and EU
Alert
FDA Foreign Inspections: Key developments and strategic shifts
Alert
Life Science Private Equity Risk
Alert
Trump Administration Initiates Section 232 Investigations on Pharmaceuticals and Semiconductors
Alert
China Released First-of-Its-Kind Compliance Guidelines for Healthcare Companies to Prevent Commercial Bribery Risks
Alert
The CMA’s “revised” approach to UK merger control and impact on M&A
Alert
First International Procurement Instrument case relating to EU medical devices in China’s public procurement market. The key question is what comes next?
Alert
UK expands its merger control regime and the CMA’s powers with the Digital Markets, Competition & Consumers Act
Alert
United States Finalizes Section 301 Tariff Increases on Imports from China
Alert
Australia’s proposed mandatory merger notification thresholds announced
Article
The Current Status of FTC’s Orange Book Listings Challenge: A Mixed Bag
Article
United States: Pharmaceutical Antitrust 2025
Alert
Federal Circuit Limits the Application of Obviousness-Type Double Patenting for Patents in the Same Family
Alert
Three Drug Pricing Litigation Issues to Watch in the Second Half of 2024
Alert
Merger reform exposure draft proposes broad competition law reform
Alert
USTR Issues Details of the Proposed Section 301 China Tariff Increases, Seeking Public Input
Alert
Biden Administration Expands Section 301 Tariffs on Imports from China, Targeting Green Energy, Metals, Minerals, Port Cranes, Medical Supplies, and Semiconductors
Article
German financing market ready to reset after a challenging year
Event
ABA 2024 Antitrust Spring Meeting
Alert
DOJ Antitrust Division Announces Deferred Prosecution Agreements with Two Pharmaceutical Companies Containing “Extraordinary” Divestiture Remedy
Article
United States: Pharmaceutical Antitrust 2024
Alert
Where Things Stand on Drug Pricing at the Halfway Point of 2023
Insight
European biotech enjoys a burst of dealmaking activity
M&A Explorer | The first quarter saw a string of transactions after a punishing year for the sector
Insight
Tech continues to dominate
Last year was a volatile 12 months for the tech sector, with a steep sell-off in growth stocks and a drop in IPOs—but, although the sector was down, it was by no means out
Alert
EU Court of Justice clarifies that all exchanges with external counsel are privileged – an important development amidst a dawn raid uptick in Europe
Insight
PMB performs as pharma groups repurpose their portfolios
After a year of historic profits in 2021 following the mass roll-out of COVID-19 vaccines and related treatments, big pharma companies armed with cash for deals have been shifting their attention
Insight
Global healthcare M&A delivers strong performance
M&A Explorer | Dealmaking in the pharma, medical and biotech (PMB) subsectors was driven by both old and new market trends in 2022
Alert
Five Drug Pricing Issues to Watch in 2023
Alert
Strong Medicine: Using Investment Treaties to Mitigate Foreign Regulatory Risk in the Life Sciences
Article
United States: Pharmaceutical Antitrust 2023
Alert
2022 Drug Pricing Update: States Continue Legislative Push Even As Congress Passes Long Sought Changes
Insight
Big pharma firms return to the deal table in H1
Cash-rich pharma firms look set for a buying spree, as favorable biotech valuations and patent expirations incentivize dealmaking
Alert
EU General Court confirms European Commission's Article 22 EUMR referral policy
Alert
Federal Legislators and FTC Keep PBMs Center Stage in Drug Pricing Debate
Alert
Smart Cities
At its core, the smart city is about people and improving the quality of our everyday lives.
Alert
Biogen rehearing denied: Is SCOTUS the next step?
Alert
Federal District Court holds that California's anti reverse payment law is enforceable, but only against settlements "negotiated, completed, or entered" in California
